Skip to main content
. 2009 Mar 10;17(6):980–991. doi: 10.1038/mt.2009.45

Figure 2.

Figure 2

Animal measures. (a) Weekly change in body mass and weekly FI (b) before and after rAAV2/5-administration (week 0). Open circles represent the hyp-GFP group (n = 7), open triangles SN-GFP (N = 8), closed circles hyp-GDNF (n = 6), and closed triangles SN-GDNF (n = 7). The SN-GDNF group displayed a significant decrease in body weight as compared to the GFP control from week 2 (*) and when compared to the hyp-GDNF (#) from week 3. The hyp-GDNF group displayed a significant weight loss as compared to the GFP control from week 6 (%) (P < 0.01). There was also a transient decrease in FI (b) in the SN-GDNF animals when compared to the GFP control (25%) 2–5 weeks following the rAAV2/5 injection (*) and the hyp-GDNF group (11%) (weeks 2,3) (#). The hyp-GDNF-injected animals consumed 11% less food 3–4 weeks following the injections as compared to the GFP control (%) (P < 0.001). Cumulative FI postinjection (b-inset) was significantly lower in the SN-GDNF group when compared to the GFP control and the hyp-GDNF group (P < 0.001). Activity measures (c) done at ~45 days postsurgery indicate no significant differences in activity among the groups. (d) ELISA measurements specific for the transgene indicate that there was no difference due to injection site, however, hypothalamic GDNF levels were >50-fold in measurements taken from the striatum and NAcc. ELISA, enzyme-linked immunosorbent assay; FI, food intake; GDNF, glial cell line–derived neurotrophic factor; GFP, green fluorescent protein.